VP1-2024: RATIONALE-315: Event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC)
Titel:
VP1-2024: RATIONALE-315: Event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC)
Auteur:
Yue, D. Wang, W. Liu, H. Chen, Q. Chen, C. Liu, L. Zhang, P. Zhao, G. Yang, F. Han, G. Cheng, Y. Yu, B. Yang, Y. Chen, H. Jiang, J. Yao, B. Wang, S. Wang, R. Zheng, W. Wang, C.